WebMD

How Copaxone Affects Your Body

Glatiramer acetate (Copaxone) is an injectable drug that treats relapsing forms of multiple sclerosis in adults. It’s a man-made version of a protein similar to one found in myelin, an insulating ...
Healthline

All About Copaxone

Copaxone (glatiramer) is a prescription drug that’s used in adults to treat certain types of multiple sclerosis and clinically isolated syndrome. Copaxone comes as a liquid solution that you’ll inject ...
Healthline

Side Effects of Copaxone: What You Need to Know

Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
FierceBiotech

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
FiercePharma

New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently

JERUSALEM--(BUSINESS WIRE)--Jan. 28, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental ...
FiercePharma

TEVA ANNOUNCES COPAXONE® REACHES ONE MILLION PATIENT YEARS OF EXPERIENCE IN THE TREATMENT OF MULTIPLE SCLEROSIS

Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
Business Wire

Teva’s COPAXONE® 40mg – Favorable Response from European Patent Office

COPAXONE ® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE ® are redness, pain, swelling, ...
Business Wire

Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
FierceBiotech

Treatment with COPAXONE® in Multiple Sclerosis Demonstrated Remyelination and Neuroprotective Effects in a Preclinical Set

Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
JD Supra

Invalidity Of Copaxone Patents Supported By Statements To FDA

In In re Copaxone Consolidated Cases, the Federal Circuit affirmed the district court decision finding four patents directed to a specific dosing regimen for using COPAXONE® 40 mg/ml to treat patients ...
Nasdaq

Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be ...